ImmunoPrecise Antibodies Management
Management criteria checks 2/4
ImmunoPrecise Antibodies' CEO is Jennifer Bath, appointed in Feb 2018, has a tenure of 6.92 years. total yearly compensation is CA$1.01M, comprised of 72.8% salary and 27.2% bonuses, including company stock and options. directly owns 1.49% of the company’s shares, worth €256.95K. The average tenure of the management team and the board of directors is 3.5 years and 2.5 years respectively.
Key information
Jennifer Bath
Chief executive officer
CA$1.0m
Total compensation
| CEO salary percentage | 72.8% |
| CEO tenure | 6.9yrs |
| CEO ownership | 1.5% |
| Management average tenure | 3.5yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2024 | n/a | n/a | -CA$28m |
| Jul 31 2024 | n/a | n/a | -CA$28m |
| Apr 30 2024 | CA$1m | CA$732k | -CA$27m |
| Jan 31 2024 | n/a | n/a | -CA$14m |
| Oct 31 2023 | n/a | n/a | -CA$16m |
| Jul 31 2023 | n/a | n/a | -CA$21m |
| Apr 30 2023 | CA$2m | CA$714k | -CA$27m |
| Jan 31 2023 | n/a | n/a | -CA$26m |
| Oct 31 2022 | n/a | n/a | -CA$25m |
| Jul 31 2022 | n/a | n/a | -CA$23m |
| Apr 30 2022 | CA$2m | CA$649k | -CA$17m |
| Jan 31 2022 | n/a | n/a | -CA$17m |
| Oct 31 2021 | n/a | n/a | -CA$15m |
| Jul 31 2021 | n/a | n/a | -CA$10m |
| Apr 30 2021 | CA$2m | CA$503k | -CA$7m |
| Jan 31 2021 | n/a | n/a | -CA$3m |
| Oct 31 2020 | n/a | n/a | -CA$3m |
| Jul 31 2020 | n/a | n/a | -CA$3m |
| Apr 30 2020 | CA$673k | CA$488k | -CA$5m |
| Jan 31 2020 | n/a | n/a | -CA$8m |
| Oct 31 2019 | n/a | n/a | -CA$8m |
| Jul 31 2019 | n/a | n/a | -CA$9m |
| Apr 30 2019 | CA$1m | CA$505k | -CA$8m |
| Jan 31 2019 | n/a | n/a | -CA$6m |
| Oct 31 2018 | n/a | n/a | -CA$6m |
| Jul 31 2018 | n/a | n/a | -CA$5m |
| Apr 30 2018 | CA$65k | CA$65k | -CA$5m |
Compensation vs Market: Jennifer's total compensation ($USD694.94K) is above average for companies of similar size in the German market ($USD459.36K).
Compensation vs Earnings: Jennifer's compensation has been consistent with company performance over the past year.
CEO
Jennifer Bath
6.9yrs
Tenure
CA$1,005,342
Compensation
Dr. Jennifer Lynne Bath, Ph D, has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018.Dr. Bath served as the Global Director of Client Relations at Ald...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Non-Independent Director | 6.9yrs | CA$1.01m | 1.49% € 256.9k | |
| Chief Financial Officer | 1.3yrs | CA$865.30k | 0.060% € 10.3k | |
| Chief Scientific Officer & Interim General Manager of IPA Europe | 3.5yrs | CA$276.93k | 0.028% € 4.9k | |
| Vice President of Commercial Services | no data | CA$273.60k | no data |
3.5yrs
Average Tenure
Experienced Management: TQB's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Non-Independent Director | 6.7yrs | CA$1.01m | 1.49% € 256.9k | |
| Independent Director | 1.3yrs | CA$118.45k | no data | |
| Member of Strategic Advisory Board | 3.7yrs | no data | no data | |
| Independent Chairman of the Board | 1.3yrs | CA$117.69k | 0.0058% € 1.0k |
2.5yrs
Average Tenure
Experienced Board: TQB's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 17:13 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmunoPrecise Antibodies Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Tania Armstrong-Whitworth | Cormark Securities Inc. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |